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ABSTRACT
Purpose: To define the role of the DNA repair protein apurinic/apyrimidinic 
endonuclease 1 (APE1) in predicting the prognosis and chemotherapeutic response 
of non-small cell lung cancer patients receiving platinum-containing chemotherapy. 
Results: Our investigations found that serum APE1 level was significantly 
elevated in 229 of 412 NSCLC patients and correlated with its level in tissue  
(r2 = 0.639, p < 0.001). The elevated APE1 level in both tissue and serum of 
patients prior to chemotherapy was associated with worse progression-free survival  
(HR: 2.165, p < 0.001, HR: 1.421, p = 0.012), but not with overall survival. After 6 
cycles of chemotherapy, a low APE1 serum level was associated with better overall 
survival (HR: 0.497, p = 0.010). 
Experimental Design: We measured APE1 protein levels in biopsy tissue from 
172 NSCLC patients and sera of 412 NSCLC patients receiving platinum-based 
chemotherapy by immunohistochemistry and a newly established sensitive and 
specific enzyme-linked immunosorbent assay, respectively. APE1 levels in sera of 
523 healthy donors were also determined as control. 
Conclusions: Our studies indicate that APE1 is a biomarker for predicting 
prognosis and therapeutic efficacy in NSCLC. The chemotherapy-naïve serum APE1 
level, which correlated with its tissue level inversely associated with progression-
free survival of platinum-containing doublet chemotherapy, whereas post-treatment 
serum APE1 level was inversely associated with overall survival.
INTRODUCTION 
Current pan-cancer analyses have revealed that 
most cancers are driven by mutations in a subset of genes, 
highlighting the role of mutagenesis and genomic instability 
in the process of carcinogenesis [1]. In addition, during 
cancer treatment, the induction of DNA lesions is the 
predominant cytotoxic mechanism of both chemotherapy 
and radiotherapy. Thus, as guardians of the genome, DNA 
repair mechanisms serve to protect against the biological 
consequences of both endogenous and externally-induced 
DNA damage. Alterations in DNA repair during the 
evolution of cancer cells can promote carcinogenesis, 
as well as regulate resistance to genotoxic chemo- and 
radio-therapies [2]. Thus, further information about the 
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dynamics of DNA repair in cancer etiology presents an 
opportunity, not only to better understand the development 
of cancer, but also to advance the application of molecular-
driven therapeutics. 
Numerous studies have revealed a potential role 
for DNA repair genes/proteins as biomarkers in different 
types of cancer, including non-small cell lung cancer 
(NSCLC) (reviewed in [3]). Notably, NSCLC is a cancer 
for which genotyping of tumor cells, particularly with 
respect to epidermal growth factor receptor (EGFR) 
mutations, has demonstrated a remarkable level of success 
in treatment planning and efficacy (reviewed in [4]). An 
ideal predictive biomarker assay for tumor screening or 
for monitoring therapeutic efficacy must be reproducible, 
sensitive, specific, cost-effective and able to be executed 
rapidly. Since DNA repair proteins predominantly reside 
in the nucleus, most proteins have only been detected in 
biopsy tissues and therefore do not meet the criteria for 
a desirable biomarker. To combat this problem, efforts 
have been made to detect autoantibodies in plasma and 
serum against DNA repair-associated proteins: including 
the tumor suppressor p53 [5, 6], replication protein A 32 
[7], the DNA strand break response protein poly(ADP-
ribose) polymerase 1 (PARP1), the breast cancer 
associated proteins 1 and 2 (BRCA1/2) [8], the human 
mismatch repair proteins, MutS homolog 2 (hMSH2) and 
postmeiotic segregation increased 1 (hPMS1) [9], and 
the DNA non-homologous end-joining factor Ku [10]. 
However, the production of autoantibodies against DNA 
repair-associated proteins depends on antigen exposure 
and the immune status of the subjects. Although p53 
protein can be detected in serum [11], to our knowledge, 
until recently, no core DNA repair enzyme, other than 
apurinic/apyrimidinic endonuclease 1 (APE1) , has been 
reported to be found in serum. 
APE1 is an essential, multi- functional protein 
possessing both DNA repair and transcriptional regulatory 
activities. Most notably, it participates in the base 
excision repair (BER) pathway, and its activity accounts 
for over 95% of the total AP endonuclease activity in 
human cells, making it critical to overall BER capacity 
(reviewed in [12]). In addition, APE1 regulates the 
DNA binding affinity of several important transcription 
factors, including NF-κB, AP-1 and p53 through redox-
dependent and -independent mechanisms. APE1 protein 
expression has been measured primarily in formalin-fixed, 
paraffin-embedded (FFPE) biopsy tissue sections from 
patients and matched controls or pre-cancerous tissue 
using immunohistochemistry (IHC). Collectively, studies 
from our group and others have shown that elevated 
nuclear APE1 protein levels, as well as cytoplasmically 
accumulated APE1, are associated with poor prognosis 
and chemoresistance (reviewed in [12]). 
In addition to direct tissue detection of APE1, this 
protein has also, surprisingly, been indirectly detected 
through the presence of anti-APE1 autoantibodies 
discovered initially in the context of systemic lupus 
erythematosus (SLE) [13]. Based on this observation, 
we speculated that APE1 protein could also be present in 
human serum under other pathological conditions. Our 
laboratory was the first to report the presence of APE1 in 
serum from peripheral blood samples of NSCLC patients 
[14]. Although statistical significance was not reached 
in that study due to the relatively small sample size, we 
still observed an elevation of serum APE1 (from hereon 
referred to as sAPE1) levels in NSCLC patients associated 
with advanced stages of the disease. 
Based on the above preliminary observations, 
we investigated herein APE1 as a biomarker for 
NSCLC diagnosis and response to platinum-containing 
chemotherapy. We initially measured APE1 protein levels 
in biopsy tissue of NSCLC patients receiving platinum-
based doublet chemotherapy by IHC, with the goal of 
correlating APE1 tissue expression with therapeutic 
response. To improve our analyses, we increased our 
sample size for greater power, and in order to accurately 
measure trace amounts of sAPE1, we established a 
sophisticated enzyme-linked immunosorbent assay 
(ELISA) with high sensitivity and a wide linear-range of 
detection. Our investigations indicate that (i) increased 
APE1 protein levels in NSCLC biopsy tissue are 
correlated with a decreased sensitivity to chemotherapy 
and (ii) sAPE1 is significantly elevated in NSCLC patients 
and enhances diagnostic power of carcinoembryonic 
antigen (CEA). In addition, elevated APE1 levels are 
associated with shorter progression-free survival (PFS) 
after chemotherapy, suggesting that APE1 is a promising 
biomarker for monitoring therapeutic efficacy.
RESULTS
Expression of APE1 protein in NSCLC tissue
APE1 expression analysis was conducted on a 
cohort of 172 advanced NSCLC patients, for which the 
clinicopathological characteristics are summarized in 
Table 1. IHC revealed that APE1 nuclear expression is 
present in 73.25% of the tissue samples, with exclusive 
nuclear expression in 33.72% and dual expression in 
both the nucleus and cytoplasm in 39.53% of the tissues 
(representative images shown in Figure 1). 
Tissue APE1 expression level is inversely 
associated with platinum-based chemotherapy 
response 
Among the 172 patients, 136 (79.07%) received 
taxol/docetaxel plus cisplatin (TP) regimens and 36 
(20.93%) received gemcitabine plus cisplatin (GP) 
regimens with an average cycle number of four (range 
from 2 to 8). The responses to the chemotherapy included: 
2 complete response (CR) (1.16% of evaluated patients), 
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53 partial response (PR) (30.81%), 65 stable disease (SD) 
(37.79%), and 52 progressive disease (PD) (30.23%). 
The objective response rate (ORR) in the group with 
high APE1 expression was 25.40%, while the ORR 
was 50.00% in the group with low APE1 expression 
(OR 5.233; 95% CI 2.029-13.443; p = 0.001, shown in 
Table 2). Kaplan–Meier survival curves showed that the 
APE1 negative group had a significantly longer median 
PFS (10.3 vs. 8.0 months, p = 0.016). Although not 
statistically significant, overall survival (OS) is longer in 
the APE1 negative group as well (17.1 vs. 10.9 months, 
p = 0.263) (Figure 2). However, NSCLC patients 
with either exclusively nuclear or combined nuclear/
cytoplasmic expression of APE1 had almost the same 
median PFS (8.4 vs. 7.7 months) and OS (10.7 vs. 
11.1 months). In addition, the APE1 low-expression group 
treated with TP regimens vs. GP regimens had almost 
the same response rate (48.48% vs. 53.85%, p = 0.175), 
median PFS (11.1 vs. 7.4 months, p = 0.277) and OS 
(17.0 vs. 17.5 months, p = 0.742). These data suggest that 
APE1 is a predictive factor for platinum sensitivity, but not 
for the other agents (taxol/docetaxel and gemcitabine) used 
in the different chemotherapy regimens. A multivariate 
Cox regression analysis showed that high tissue APE1 
expression is independently associated with shorter PFS 
(HR 2.165; 95% CI: 1.455–3.221; p < 0.001) and OS 
(HR 2.543; 95% CI 1.639–3.947; p < 0.001) (Table 2). 
sAPE1 was positively associated with APE1 
expression in tumor tissue
Although APE1 levels in biopsy tissue showed an 
inverse correlation with response to platinum-containing 
chemotherapy, biopsy tissues are not always easy to 
obtain, which makes it difficult to monitor treatment 
responsiveness during chemotherapy. Our previous study 
showed that elevated APE1 protein could be detected in 
the serum of lung cancer patients, although statistical 
significance was not reached [14]. In the current study, we 
sought to measure the chemotherapy-naïve sAPE1 level by 
Table 1: The demographic and clinical characteristics of tissue cohort
Characteristics Number
Age
 Median (Range) 60.46 (34–84)
 < 60 82 (47.67%)
 > = 60 90 (52.33%)
Gender
 Female 55 (31.98%)
 Male 117 (68.02%)
Stage
 III 63 (36.63%)
 IV 109 (63.37%)
Histopathology
 Adenocarcinoma 106 (61.63%)
 Squamous cell carcinoma 34 (19.77%)
 Mixed/other NSCLC 32 (18.60%)
Smoking status
 Never 69 (40.12%)
 Ever-smoker 103 (59.88%)
Performance status
 0 103 (59.88%)
 1 56 (32.56%)
 2 13 (7.56%)
APE1 expression score
 0 19 (11.04%)
 1 27 (15.70%)
 2 65 (37.79%)
 3 61 (35.47%)
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using a newly established ELISA protocol. Using a cohort 
of 52 advanced NSCLC patients randomly picked from the 
tissue cohort, along with corresponding pre-treatment serum, 
we explored whether sAPE1 level was associated with its 
tissue expression. Based on Spearman’s correlation analysis, 
the data show a positive relationship between sAPE1 and 
tissue expression (r2 = 0.639, p < 0.001). Intriguingly, the 
degree of cytoplasmic localization of APE1 is not associated 
with sAPE1 level based on our analysis.
Increased APE1 protein level detected in serum 
of NSCLC patient
Following up on the pilot study above, we next tested 
if sAPE1 was elevated in NSCLC patients by measuring 
the chemotherapy-naïve sAPE1 level in a cohort of 412 
advanced NSCLC patients and 523 healthy donors. Four 
hundred subjects (1:1) were randomly selected from the 
whole research set, matched by age and gender (Table 3). 
Our data revealed a significant elevation of sAPE1 in 
NSCLC patients compared with controls (Median level: 
0.159 vs. 0.091, p < 0.001, Figure 3A). The same trend 
was also observed in stage IV patients compared with 
other patients with earlier stages (Figure 3B).
The multivariate analysis indicates that 
chemotherapy-naïve sAPE1 level could be an independent 
predictive factor for NSCLC (OR: 6.082, 95% CI: 
2.278–13.561, p < 0.001, Table 4). The area under the 
curve (AUC) of the receiver operator characteristic (ROC) 
curve for sAPE1 level was 0.653 (Figure 4). The Youden’s 
index therefore determined the appropriate sAPE1 
predictive value to be 0.135 ng/ml. At this level, the 
sensitivity, specificity and accuracy of sAPE1 for NSCLC 
diagnosis was 55.58%, 70.75% and 64.06%, respectively. 
In addition, our analyses displayed an increased diagnostic 
sensitivity and accuracy of 53.69% and 77.39% for the 
combination of sAPE1 and CEA levels, compared to 
42.61% and 74.81% of CEA alone (Table 4). 
Higher sAPE1 level is associated with poor 
chemotherapeutic outcomes
Our previous laboratory results indicated that APE1 
is a responsive gene for platinum treatment and that 
deficiency of APE1 in cancer cells increases sensitivity to 
platinum-based chemotherapy [15]. A chemotherapy-naïve 
sAPE1 level higher than 0.135 ng/ml was categorized as 
an elevated level (see above). A higher disease control rate 
(DCR) was observed in patients with chemotherapy-naïve 
sAPE1 levels below the cut-off value (79.69% vs. 59.26%, 
p = 0.001, Figure 5). Conversely, elevated sAPE1 is an 
independent factor for poor NSCLC treatment response 
(Table 5). 
Survival analysis revealed that patients with 
chemotherapy-naïve sAPE1 levels below the cut-off 
value exhibit an increased PFS compared to those 
Figure 1: The tissue expression of APE1 in non-small cell lung cancer. APE1 protein was scored for four categories: (A) score 
0, (B) score 1+, (C) score 2+ and (D) score 3+, and was detected in three subcellular patterns in tumor tissues: the nuclear, the cytoplasm 
and both in nucleus and cytoplasm. Original magnification: ×100.
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Table 2: Association of APE1 tissue subcellular location with the outcomes of NSCLC receiving 
chemotherapy
Treatment response Progression-free survival Overall survival
Number 
of cases CR+PR SD+PD
ORR
(%)




Multivariable COX  
regression
OR  
 (95% CI) P value
HR  
(95% CI) P value
HR 
(95% CI) P value
APE1 tissue expression
Low 46 23 23 50.00 10.30 17.10
High 126 32 94 25.40 5.233 (2.029–13.443) 0.001 8.00
2.165  
(1.455–3.221) < 0.001 10.90
2.543  
(1.639–3.947) < 0.001
APE1 tissue subcellular location
Low expression 46 23 23 50.00 10.30 17.10










Treatments in APE1 low expression
Paclitaxel 33 16 17 48.48 11.10 17.00
Other 13 7 6 53.85 0.353  (0.078–1.590) 0.175 7.40 17.50 0.742
CR: complete response, PR: partial response, SD: stables disease, PD: progressive disease, CI: confidence interval, ORR: objective response rate.
Figure 2: The association of tissue APE1 expression with outcomes of NSCLC. Kaplan-Meier univariate analysis of 
(A) progression-free survival (10.3 vs. 8.0 months, p = 0.016) and (B) overall survival (17.1 vs. 10.9 months, p = 0.263) for patients with 
NSCLC showing low expression of tissue APE1 and patients with NSCLC showing high expression of tissue APE1, (C) progression-free 
survival (8.4 vs. 7.7 months, p = 0.035) (D) overall survival (10.7 vs. 11.1 months, p = 0.305) for patients with NSCLC showing negative tissue 
expression and patients with NSCLC showing exclusive nuclear expression or combined nuclear/cytoplasmic expression of tissue APE1.
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with an elevated level (6.0 vs. 10.0 months, p = 0.001, 
Figure 6A), although low serum levels were not beneficial 
for OS (29.0 vs. 29.0 months, Figure 6B). Again, elevated 
sAPE1 level is an independent risk factor for PFS in 
NSCLC receiving platinum-containing chemotherapy 
(HR: 1.421, 95% CI: 1.079–1.872, p = 0.012, Table 5). 
The pattern of sAPE1 level alteration during 
chemotherapy is associated with the therapeutic 
response of NSCLC
To explore the possibility of monitoring therapeutic 
efficacy using sAPE1 changes during chemotherapy, we 
tracked the sAPE1 level of 236 cases of NSCLC patients 
at ~1 month after the sixth cycle. All subjects were 
categorized into these four groups: group L are those 
patients whose sAPE1 level started and remained below 
the cut off (< 0.135 ng/ml) during the treatment; group E 
had an initially low sAPE1 level, which was elevated over 
the cut-off after treatment; group H consists of patients 
whose sAPE1 level started and remained above the cut 
off (> = 0.135 ng/ml) during the treatment; and group R 
includes those patients that had an initially high sAPE1 
level, which was reduced to below the cut-off. Compared 
with group H, the other groups demonstrated significantly 
decreased risks of progression in disease after treatment 
(HR: 0.449, 95% CI: 0.301–0.670, p < 0.001 for group L; 
HR: 0.612, 95% CI: 0.406–0.922, p = 0.019 for group R; 
Table 3: The demographic and clinical characteristics of serum cohort
Cases (n = 200) Controls (n = 200) P value
Age
 Mean ± SD 58.42 ± 9.58 56.98 ± 10.19 1.000
 < 60 127 (63.5%) 127 (63.5%)
 > = 60 73 (36.5%) 73 (36.5%)
Gender 0.765
 Male 127 (63.5%) 124 (62.0%)
 Female 73 (36.5%) 76 (38.0%)
Smoking Status* 0.036
 Non-smoker 107 (53.5%) 86 (43.0%)
 Smoker 93 (46.5%) 114 (57.0%)
Family History of Cancer 0.663
 Negative 171 (85.5%) 174 (87.0%)
 Positive 29 (14.5%) 26 (13.0%)
Serum APE1 level (ng/ml)
 Median (range) 0.159 (0~6.48) 0.091 (0~0.98) < 0.001
*Two Controls had no exact history of smoking.
Figure 3: The sAPE1 level in NSCLC patients and healthy subjects assessed by ELISA. The sAPE1 level (A) between 
NSCLC cases and controls and (B) between NSCLC patients with stage I–III and stage IV.
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HR: 0.652, 95% CI: 0.445–0.955, p = 0.028 for group E). 
In the survival analysis, compared to group H, all the 
other groups exhibited a distinct increase in median PFS 
(Figure 6C). The three groups also had a longer median 
OS compared with group H (Figure 6D). Moreover, the 
multivariate Cox regression confirmed that compared with 
group H, the other groups were independent protective 
factors for PFS; and while only groups L and R were 
associated with better outcomes for OS, no statistical 
difference was observed between groups E and H 
(Table 5). These results strongly suggest that monitoring 
sAPE1 level could be a potential strategy to predict 
efficacy of platinum-containing chemotherapy in NSCLC 
patients. 
DISCUSSION
Unlike the targeted drugs utilized in the treatment 
of NSCLC, such as the EGFR-TKIs and ALK inhibitors, 
chemotherapeutic agents, including platinum, are usually 
applied to cancer patients without any specific gene target 
in mind, but instead are based on established response 
rates in previous trials. While collective efforts have been 
made to identify predictive biomarkers for the efficacy 
of chemotherapy, little progress have been made in this 
arena, particularly as it relates to DNA repair [3]. In the 
current study, we observed that in the tumor tissue, APE1 
protein, an essential DNA repair enzyme in the BER 
pathway, could be a promising predictive biomarker for 
the responses of NSCLC patients receiving platinum-
containing chemotherapy. Moreover, this previously 
reported nuclear protein was detected in the serum of 
NSCLC patients, and its level in the serum was directly 
correlated with the level measured in cancer tissue 
[12, 16, 17]. In addition, we describe herein, for the first 
time to our knowledge, that alteration of sAPE1 after 
Table 4: Multivariable logistic regression analysis of APE1 and CEA level in sera of NSCLC
Characteristics






interval (95% CI) P value Sensitivity Specificity Accuracy
sAPE1 level (ng/ml) 1.805 6.082 2.278–13.561 < 0.001 55.58% 70.75% 64.06%
CEA level (ng/ml) 0.252 1.286 1.187–1.394 < 0.001 42.61% 99.81% 74.81%
sAPE1 and CEA combination 0.999 2.716 2.104–3.507 < 0.001 53.69% 95.79% 77.39%
*Adjusted with age, gender, smoking status and family history of cancer.
Figure 4: The ROC curves of sAPE1 level for diagnosing NSCLC. The diagnostic potentials of quantifying sAPE1 were 
assessed by ROC curves. The AUC value was 0.653. The cut-off value (0.135 ng/ml) was determined by Youden’s index. 
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chemotherapy is significantly associated with response 
and PFS of platinum-containing chemotherapy. Thus, our 
data indicate that monitoring the sAPE1 level could be an 
auxiliary strategy for physicians to predict the response to 
chemotherapy.
The cytotoxicity of platinum drugs is associated 
with their ability to crosslink DNA strands, which can 
lead to defective DNA replication and increased strand 
breaks [18]. Therefore, it is reasonable to explore 
biomarkers associated with platinum resistance within 
DNA repair pathways [19], such as the excision repair 
cross-complementation group 1 (ERCC1), which is the 
most studied candidate for predicting platinum-containing 
chemotherapy response. ERCC1 protein plays an essential 
role in nucleotide excision repair (NER), in which it 
cleaves DNA structures near the site of the platinum–DNA 
adduct, thereby allowing eventual removal of the lesion. 
Based on the hypothesis that DNA repair mechanisms 
play a critical role in dictating overall genotoxic agent 
responsiveness, retrospective and prospective studies have 
been performed to explore the clinical correlation between 
ERCC1 expression (at both the RNA and protein level, as 
well as with respect to SNPs) with prognosis and relevant 
chemotherapy response. Previous clinical trials, however, 
have found limited, if not negative, predictive effects of 
ERCC1 expression (as measured by IHC in tumor tissue) 





N OR (95% CI) P value Median HR (95% CI) P value Median HR (95% CI) P value
Initial 
level
< 0.135 128 10.00 29.00
> = 0.135 108 2.600 (1.413–4.784) 0.002 6.00 1.421(1.079–1.872) 0.012 29.00 0.210
Change 
trends
High (H) 58 4.00 18.00
Elevated (E) 66 0.332 (0.146–0.753) 0.008 8.00 0.652 (0.445–0.955) 0.028 29.00 0.649 (0.395–1.066) 0.088
Reduced (R) 50 0.429 (0.183–1.009) 0.052 8.00 0.612 (0.406–0.922) 0.019 38.00 0.510 (0.288–0.902) 0.021
Low (L) 62 0.188 (0.075–0.471) < 0.001 12.00 0.449 (0.301–0.670) < 0.001 32.00 0.497 (0.291–0.849) 0.010
DCR: Disease control rate; PFS: Progression-free survival; OS: Overall survival.
Figure 5: The distribution of treatment responses in different initial sAPE1 level. The initial sAPE1 levels were determined 
before exposure to any chemotherapeutic drugs by ELISA. Comparison of patients with initially low levels (< 0.135 ng/ml) of sAPE1 
versus those with high levels (> = 0.135 ng/ml) showed a difference in response to platinum-containing chemotherapy (p = 0.001).
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on the efficacy of platinum-containing chemotherapy [20]. 
Our current study also analyzed the correlation between 
ERCC1 expression in biopsy tissue and efficacy of 
platinum-containing chemotherapy in the same cohort in 
which APE1 expression was measured. In agreement with 
the majority of previous studies, we found that although 
ERCC1 expression is inversely associated with ORR 
for the platinum-containing chemotherapy receivers, the 
responders did not have a longer PFS, which is considered 
to be a key efficacy marker. In addition, ERCC1 
expression is inversely correlated with OS, making it a 
poor predictive marker overall (Table 6). 
Our analysis conducted here found that high 
APE1 tissue expression is significantly correlated with 
reduced ORR, and in turn a shorter PFS, suggesting 
APE1 level could be an effective predictive biomarker 
for chemotherapy. However, APE1 is not associated with 
OS according to our analyses, implying more complex 
roles of APE1 in the evolution of NSCLC, perhaps 
reflecting the diversity of its biological functions. As OS 
could be affected by many factors, including side effects 
of chemotherapy, we postulate that APE1 plays a role 
in coping with the effects of reactive oxygen species 
produced by platinum agents, as described previously 
[21]. Future studies are needed to analyze the role of APE1 
in affecting subsequent treatment responses after standard 
Table 6: Association of ERCC1 tissue expression with the outcomes of NSCLC receiving 
chemotherapy
Treatment response Progression-free survival Overall survival
Number 






ORR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
ERCC1 tissue expression
Low 94 39 55 41.49 9.8 14.4
High 78 16 62 20.51 3.094(1.351–7.086) 6.8
2.917 
(2.160–3.939) < 0.001 10.3
2.460
(1.613–3.753) < 0.001
CR: complete response, PR: partial response, SD: stables disease, PD: progressive disease, CI: confidence interval, ORR: objective response rate.
Figure 6: The associations of sAPE1 level and sAPE1 level change pattern with outcomes of NSCLC. Kaplan-Meier 
univariate analysis of (A) progression-free survival (10.0 vs. 6.0 months, p = 0.001) and (B) overall survival (29.0 vs. 29.0 months, 
p = 0.137) for NSCLC patients with a low sAPE1 level compared to those with a high sAPE1 level. (C) progression-free survival (E vs. 
H: 8.0 vs. 4.0 months, p = 0.010; R vs. H: 8.0 vs. 4.0 months, p = 0.030, L vs. H: 12.0 vs. 4.0 months, p < 0.001) and (D) overall survival 
( E vs. H: 29.0 vs. 18.0 months, p = 0.065, R vs. H: 38.0 vs. 18.0 months, p = 0.024, L vs. H: 32.0 vs. 18.0 months, p = 0.016) for NSCLC 
patients with sAPE1 change patterns E, R, L compared to those with sAPE1 change pattern H.
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chemotherapy. 
In the present study, we have described a role 
for sAPE1 in evaluating the effectiveness of platinum-
containing chemotherapy for NSCLC patients. The APE1 
protein was initially reported to be present in serum by our 
group, and its level, although not statistically significant, 
was observed to be elevated in NSCLC patients [14]. In 
our current study, we report that APE1 serum level was 
significantly elevated in NSCLC patients, in agreement 
with reports for other cancers including bladder cancer 
[17]. The discrepancy with our prior work could be, we 
postulate, due to the following circumstances: a) the 
overall APE1 serum level was low and the sensitivity 
of the previous ELISA assay was too low to distinguish 
a difference between the levels in cancer patients from 
even lower levels in healthy donors; b) as APE1 level is 
altered by chemotherapeutic agents, only pretreatment 
or chemotherapy-naïve serum samples were analyzed 
in the current study, which should represent the cancer-
associated level; or c) simply owing to the larger sample 
size in the present study. 
Our results show that APE1 is a strong biomarker 
for NSCLC, and that combining it with a previously 
recognized biomarker for NSCLC, CEA, further enhances 
the power of both, but the use of sAPE1 as a biomarker 
for other cancers, such as small cell lung cancer (SCLC), 
needs to be explored. We found that the pretreatment level 
of sAPE1 has a similar ability to predict chemotherapy 
efficacy as compared to its tissue level. More importantly, 
monitoring sAPE1 alteration after chemotherapy is also 
beneficial for prediction of the response, making it a more 
feasible and informative biomarker than ERCC1 tissue 
expression. Intriguingly, our data unexpectedly revealed 
that patients with low initial sAPE1 level (below cut-off 
value), which increased to above the cut-off value during 
chemotherapy, had the same PFS as patients with a high 
initial and then reduced level during chemotherapy, 
suggesting that the initial level as well as changes in 
sAPE1 during the process of chemotherapy are important 
to therapeutic efficacy. Moreover, our study highlights 
that low post-treatment sAPE1 levels are associated with 
longer OS, irrespective of the initial level of sAPE1; 
further emphasizing that monitoring of sAPE1 could 
predict the efficacy of chemotherapy. 
As a protein mainly localized in the nucleus, the 
source of sAPE1, whether it be from normal or cancer 
cells, is currently unknown and the focus of ongoing 
investigations. In our present study, we show a direct 
correlation between serum and tissue APE1 levels in the 
cohort we analyzed. It is unlikely that sAPE1 originates 
from passive release by a necrotic process, because 
we analyzed the samples from untreated subjects, and 
laboratory experiments showed that supernatant APE1 
levels were nearly unchanged when cultured A549 cells 
were treated with increased doses of cisplatin (data 
not shown). This observation makes it tenable that the 
presence of APE1 in serum is due to an active process, 
such as secretion or through an exosomal pathway. Our 
laboratory data indicate that when detecting APE1 in 
serum treated with 1% Triton-X100 detergent, APE1 
levels remain unchanged, suggesting that APE1 exists in 
serum likely as the protein itself, and not within vesicles, 
such as exosomes. However, APE1 is not a typical 
secretory protein as it lacks classic secretory signals 
based on protein sequence analysis. Intriguingly, there 
are reports showing that APE1 is secreted under specific 
stimuli [22, 23]. The secretion of APE1 was associated 
with its cytoplasmic translocation according to these 
reports; however, we failed to build a positive connection 
between sAPE1 and its cytoplasmic distribution. Future 
work is required to delineate the secretory mechanisms of 
APE1 and its functional purpose in the circulation, if any. 
MATERIALS AND METHODS
Study design and patient population
A total of 172 stage IIIB and IV NSCLC patients 
were enrolled for APE1 tissue assessment. All tumors 
were pathologically confirmed during August 2007 to 
August 2012 in Daping Hospital of the Third Military 
Medical University (Chongqing, China). The following 
criteria were required for inclusion in the study: 1) 
patients must have received at least two cycles of first 
line platinum-based chemotherapy with a measurable 
tumor response, and 2) the paraffin-embedded tissue 
samples must be available. All patients received the 
platinum-based doublets chemotherapy, i.e., TP regimen 
(Platinum & Paclitaxel) or GP regimen (Platinum & 
Gemcitabine). The entire treatment protocol was devised 
to follow the NCCN guidelines. Tumor response was 
evaluated after every two cycles of chemotherapy and 
was classified using RECIST (version 1.1). Demographic 
and clinical data were obtained by office interviews or 
telephone visit. The histological type, tumor stage, and 
TNM classification were analyzed according to the World 
Health Organization. The whole cohort was followed up 
every 6 weeks until the disease progressed and then every 
3 months until death. The median follow-up time was 
11 months (range, 1–43 months) measured from the onset 
of chemotherapy.
For serum research, we enrolled 412 confirmed 
NSCLC patients and 523 cancer-free controls 
randomly picked from those determined to be healthy 
by examination. All samples were obtained within a 
five-year period from January 2010 to December 2014. 
The demographic and clinical data were obtained and 
described previously. Total 400 subjects (200 cases: 
200 controls) were picked out randomly for diagnosing 
analysis from the whole research cohort matched by age 
and gender. Patients who completed at least 6 cycles of 
standard treatments and follow-ups were subsequently 
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enrolled in the analysis. The change in sAPE1 was 
observed in the first 6 months from the onset of treatments. 
To further investigate the association between sAPE1 level 
and disease outcomes, four patterns of alteration were 
defined and their differences in DCR, PFS and OS were 
analyzed (Figure 7). The whole protocol was approved by 
the Ethics Committee of Daping Hospital, Third Military 
Medical University, China and written informed consents 
were obtained from all patients and healthy controls. 
Immunohistochemical evaluation of  
paraffin-embedded tumor tissues 
The IHC was performed to determine APE1 
expression in NSCLC tissues described previously 
[24]. Protein was scored for four categories, i.e., 
score 0, no expression in tumor cells; score 1+, faint/
barely perceptible partial nuclear expression in < 10% 
of tumor cells; score 2+, weak to moderate expression of 
the entire nucleus in > 10% of tumor cells; and score 3+, 
strong expression of the entire nucleus in > 10% of tumor 
cells. Score 2+/3+ was defined as high expression, while 
score 0/1+ as low expression. We have described this 
procedure in detail in Supplementary Methods.
Purification of recombinant APE1 protein
Untagged, human recombinant APE1 protein 
was overexpressed from pETApe, according to the 
protocol described previously [25]. The supernatant after 
centrifugation was then passed through the Q FF column 
containing the balance buffer (50 mM Hepes-KOH pH 
7.5, 5% glycerol, 50 mM KCl and 1 mM DTT) and wash 
buffer (2 M NaCl) to remove impurities. Then it passed 
through the SP FF column containing the same balance 
buffer but a different wash buffer (50mM Hepes-KOH 
Figure 7: The research protocol. 172 pathologically confirmed NSCLC patients with full follow-up information were enrolled, and 
their APE1 expression in tissue was evaluated by IHC. For serum research, 412 confirmed NSCLC patients and 523 cancer-free controls 
were included. 400 subjects (1:1 for Cases: Controls) were randomly picked from the whole set and matched by age and gender for diagnosis 
analysis. Patients completing at least 6 months therapy with full follow-up information were subsequently enrolled into prognostic analysis. 
Patients were divided into two groups: those with initial serum APE1 level lower than cut-off value (< 0.135 ng/ml) and those with higher 
than cut-off value (> = 0.135 ng/ml). The pattern of sAPE1 alteration was observed in the first 6 months and categorized into 4 groups: 
group L represents patients whose sAPE1 level both began and remained below the cut-off during the first 6 months of treatment; group E 
represents patients with initially low sAPE1 levels, which became elevated above the cut-off after treatment; group H represents patients 
whose sAPE1 level both began and remained above the cut-off (> = 0.135 ng/ml) during the first 6 months of treatment; and group R 
represents patients with an initially high sAPE1 level, which was reduced to below the cut-off.
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pH 7.5, 5% glycerol, 700 mM KCl and 1 mM DTT) with 
sequentially increasing concentrations of 10%, 20%, 30%, 
50%, 80%, and 100% 2 M NaCl. After completing the 
protocol, purified APE1 protein was obtained. A sample of 
the protein was denatured and detected by electrophoresis 
and the final concentration was determined by Lowry 
assay to be 3.1 mg/ml.
Serum sample extraction and sAPE1 level 
detection
Blood samples were collected before any treatment 
and at ~1 month after 6 cycles of chemotherapy for the 
NSCLC patients or at the time of routine examination 
for healthy subjects. The serum samples were isolated 
routinely and subjected to ELISA immediately or stored 
at −80ºC for further analysis. Detailed protocol for ELISA 
can be obtained through Supplementary Methods. 
Statistics
The quantitative data was analyzed by non-
parametric test, while the categorical data was analyzed by 
chi-square analysis or Fisher’s exact test. The Spearman’s 
correlation test was performed for relationship analysis. 
The logistic regression model was constructed to evaluate 
the relationship of sAPE1 level to NSCLC diagnosis. The 
receiver operating characteristic (ROC) curve was drawn 
to estimate the diagnostic value of sAPE1. Kaplan-Meier 
analysis and Cox proportional hazard regression model 
were performed to evaluate the association between 
sAPE1 level and NSCLC treatment outcomes.
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